In Brief: ICH Guidelines
ICH Guidelines: FDA publishes final ICH guidelines on "Repeated Dose Tissue Distribution Studies, Extent of Population Exposure Required to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Threatening Conditions, Assessment of Systemic Exposure in Toxicity Studies, Dose Selection for Carcinogenicity Studies of Pharmaceuticals, Validation of Analytical Procedures and Clinical Safety Data Management" in the March 1 Federal Register. Written comments for the guidelines, which are effective immediately, may be sent to FDA's Dockets Management Branch, Room 1-23, 12420 Parklawn Drive, Rockville, Md. 20857. Contact Janet Showalter at 301/443-1382 for additional information...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth